GlassScriptPhysician profile
Cheryl L Hess
NPI 1871579441
$8,647.02
in general payments reported to CMS, 2019-2025
50 companies · $1,619 in 2025
The $1,619 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,104 · 2020: $281 · 2021: $292 · 2022: $878 · 2023: $1,098 · 2024: $1,375 · 2025: $1,619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,072 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,072.31 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,081.86 | 2019-2025 | |
| Novo Nordisk INC | $1,035.95 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $785.93 | 2021-2025 | |
| Lilly USA, LLC | $596.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $557.73 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $325.21 | 2019-2025 | Jardiance, Stiolto Respimat |
| Sanofi-Aventis U.S. LLC | $291.06 | 2019-2024 | |
| Glaxosmithkline, LLC. | $248.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $237.32 | 2019-2025 | Evenity, Otezla, Repatha |
| Merck Sharp & Dohme LLC | $204.64 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Astellas Pharma US INC | $204.62 | 2019-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $175.67 | 2022-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $169.11 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $153.84 | 2022-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $152.49 | 2019-2020 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.